The UK's first dedicated investment summit for the medical cannabis sector — bringing together institutional investors, family offices, operators, clinicians and policy leaders for two days of intelligence, deal flow and strategic dialogue.
The UK Medical Cannabis Investment Summit 2027 is the first dedicated investment summit for the UK medical cannabis sector — designed specifically for institutional capital, not for patients, not for the general public and not for the cannabis industry trade.
The UK medical cannabis market is growing rapidly. An estimated 75,000–95,000 patients now hold valid UK prescriptions, with projections to exceed 141,000 by 2028. Two of the UK's largest clinics — Releaf and Mamedica — together serve tens of thousands of patients. The sector is attracting institutional attention from family offices, venture capital and strategic healthcare investors for the first time at meaningful scale.
The Summit exists to serve that investment community — providing the intelligence, connections and deal flow context that institutional investors need to understand, evaluate and act on the UK medical cannabis opportunity.
Family office principals, CIOs and institutional allocators evaluating the UK medical cannabis sector as an emerging asset class within healthcare, life sciences and alternative investment portfolios.
VC and growth equity investors with healthcare, life sciences or consumer wellness mandates seeking exposure to the expanding UK and European medical cannabis market.
Founders and CEOs of UK medical cannabis clinics, pharmacies, cultivation facilities and patient services companies seeking institutional capital and strategic partnerships.
Pharmaceutical and life sciences companies evaluating licensing, partnership, acquisition or distribution opportunities within the UK cannabis-based medicinal products market.
Solicitors, accountants, M&A advisers and financial consultants advising clients on UK medical cannabis investment, regulatory compliance and corporate transactions.
Parliamentary advisers, MHRA representatives, NHS commissioners and academic researchers whose work directly shapes the UK medical cannabis investment environment.
The UK medical cannabis sector has spent its first eight years — from legalisation in November 2018 to the present — building its clinical and regulatory foundation. Patient numbers have grown from near-zero to an estimated 95,000. Prescribing has expanded from a handful of specialists to a network of CQC-registered private clinics serving patients across every region of the UK. The supply chain has matured. Domestic cultivation has begun. The NPCC issued its landmark "patients first" police guidance in January 2026.
2027 is the year in which the UK medical cannabis sector crosses from an emerging clinical service into an established, scalable and investable industry. The Summit is designed to mark and serve that transition — bringing institutional capital into meaningful dialogue with the sector for the first time at this level.
"The UK medical cannabis market is approaching £1 billion in annual value — and it is only getting started."— LBC / Glass Pharms, November 2025
Delegate places are strictly limited. Register now to secure your place at the UK's most significant medical cannabis investment event of 2027.
Register to Attend →